Kristin Brooks05.18.21
Recro, a CDMO providing services for complex formulation and manufacturing challenges for oral solid dose drug products, has signed a new development agreement with Astex Pharmaceuticals, Inc.
“We are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,” said Bill Hirschman, vice president of sales and marketing for Recro. “The support we have been engaged to provide represents the type of durable, trusted relationship we work every day to build with our customers. We look forward to an ever expanding partnership and wish Astex continued success.”
Recro offers capabilities from early feasibility to commercial manufacturing for oral solid dosage form development, regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
“We are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,” said Bill Hirschman, vice president of sales and marketing for Recro. “The support we have been engaged to provide represents the type of durable, trusted relationship we work every day to build with our customers. We look forward to an ever expanding partnership and wish Astex continued success.”
Recro offers capabilities from early feasibility to commercial manufacturing for oral solid dosage form development, regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
